Clinical trial
Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer
NCT00005096 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00005096 |
|---|---|
| Title | Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer |
| Official title | Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH Rhone-Poulenc Rorer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | docetaxel |
| Enrollment | 19 |
| Start date | Dec 1, 1999 |
| Primary completion | Jun 1, 2002 |
| Completion | Jun 1, 2002 |
| First posted | Mar 4, 2004 |
| Last update posted | Jul 14, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: